Brought to you by 
Galaxy Biotech licenses anti-FGF2 antibodies to Roche
05 Nov 2012
Executive Summary
Oncology antibody discovery company Galaxy Biotech LLC has licensed Roche exclusive worldwide rights to develop and market its preclinical antibody program--including lead candidate GALF2--against fibroblast growth factor 2 (FGF2) for cancer. The Big Pharma may also possibly work on other derivative compounds.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Galaxy Biotech licenses anti-FGF2 antibodies to Roche
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice